Mutations in cardiac myosin-binding protein C (cMyBP-C) are a leading cause of hypertrophic cardiomyopathy (HCM) leading to heart failure. cMyBP-C is a potential target to treat HCM-related heart failure, and there are currently no drugs available to treat this disorder. cMyBP-C is naturally regulated by phosphorylation, resulting in reduced actin binding, and phosphorylation may be cardioprotective. Therefore, compounds that bind to cMyBP-C, reducing its interaction with F-actin and mimicking phosphorylation would be highly desirable to treat cMyBP-C-associated HCM. We developed a novel high-throughput screening (HTS) fluorescence lifetime-based assay to detect small-molecule modulators of actin-cMyBP-C binding. We attached a fluorescent dye, Alexa Fluor 568 (AF), to actin at Cys374 near its cMyBP-C binding site. When combined with human cMyBP-C N-terminal fragment (C0-C2), the fluorescence lifetime of AF-actin decreases. Phosphorylation of C0-C2 increases the lifetime of AF, indicating reduced binding. Our screen was for molecules that bind C0-C2 and mimic phosphorylation effects. Screening of a 1,280-compound small-molecule library identified 3 compounds (hits) showing significant effects in the micromolar range. These hits altered the lifetime of the AF-actin-cMyBP-C complex, but not AF-actin, in a dose-dependent manner. Binding of the compounds to cMyBP-C, but not actin, was also confirmed by isothermal titration calorimetry and transient phosphorescence anisotropy. Detailed analysis of the effects of these molecules on lifetime changes and F-actin binding, measured by a cosedimentation assay, suggest that in binding to C0-C2 the change in lifetime of AF-actin is caused by factors other than reducing binding, as seen by C0-C2 phosphorylation. We conclude that this HTS assay permits detection of compounds that bind C0-C2 when bound to actin, and sets the stage for screening larger compound libraries for modulators of the actin-cMyBP-C interaction.
Read full abstract